Europe Biopharmaceutical Processing Equipment and Consumables Market by Product Type {Filtration, Chromatography [Consumables, Equipment], Disposable Bioreactors, Cell Culture Media, Shakers, Services), Application (Vaccine, mAb, R&D), and End User - Forecast to 2032
Market Trends
So far, the biopharmaceutical processing industry has been dominated by stainless-steel/reusable equipment in Europe. Most biopharmaceutical manufacturing plants in the region have fixed stainless-steel bioreactors, mixers, and bioprocessing vessels. However, in the last few years, the trend has shifted towards adopting single-use/disposable equipment. This is attributed to various advantages this equipment has over conventional stainless-steel equipment, such as reduced manufacturing costs (by eliminating cleaning and cleaning validation steps).
Besides reducing the time and labor required, single-use technologies also help reduce capital costs and energy consumption, improving efficiency. Although single-use systems generate waste from incinerating and discarding plastic materials, they still leave a smaller carbon footprint than permanent steel systems. The carbon dioxide released after generating steam for water for injection (WFI) cleaning and the steam-in-place sterilization of stainless-steel vessels, piping, and other hardware are far more than the carbon dioxide produced from manufacturing and disposal of plastic single-use systems. Thus, the usage of WFI, steam, and cleaning agents is reduced significantly by incorporating single-use platforms.
Single-use systems (SUS) are used clinically for over 80% of European bioprocessing operations. However, biomanufacturers and contract manufacturing organizations (CMOs) are expected to adopt such systems more as pipeline SUS products are increasingly approved and enter commercial production.
Click here to: Get a Free Sample Copy of this Report
Growing Focus on Continuous Bioprocessing to Drive the Growth of this Market
For a long time, batch/fed-batch mode has dominated the manufacturing of biopharmaceuticals in Europe. However, it has some limitations - it requires additional instruments for feedback control and is costly operation costs compared to continuous bioprocessing. In continuous bioprocessing, the process is performed at a single location without interruption, as there is a continuous flow of raw materials in and out of the bioreactor with the processing of the intermediate or final product—in contrast to batch culture—in which specific quantity of product is produced in a discrete volume during the same cycle of manufacture, and the process is frequently segmented into many individual steps that are often performed at separate facilities.
Moreover, continuous processing produces a quality end product with no variation and offers steady-state operation, reduced equipment size, streamlined process flow, and reduced capital costs. Due to the growing demand for innovative and complex therapies and the growing competition in the European biopharmaceuticals market, biopharmaceutical manufacturers are reconsidering manufacturing methods (shifting from batch to continuous manufacturing). Although batch manufacturing is preferred, continuous manufacturing is increasingly accepted in the pharmaceutical industry due to its commercial advantages.
Need something more specific?
A custom-scoped study can target a single segment, geography, or competitor set — or answer a board-level question this syndicated report doesn't. Tell an analyst what decision you're making and we'll scope it.